Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

All NewsJune 18, 2025

Aptevo stock spikes as new AML trial data show 85% remission rate with mipletamig triplet therapy, supported by strong safety and no CRS observed.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent